Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to
hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been
inadequate.
Primary Hyperlipidemia
GON SA ATZETI is indicated for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.
Limitations of Use
No incremental benefit of GON SA ATZETI on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. GON SA ATZETI has not been studied in Fredrickson type I, III, IV, and V dyslipidemias.

This is only the preview. Please check here for the full indication.